Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/NERVGEN-PHARMA-CORP-55763923/news/NervGen-Pharma-Announces-First-Subject-Dosed-in-Landmark-Phase-1b-2a-Clinical-Trial-for-NVG-291-in-S-44914994/?utm_source=whatsapp&utm_medium=social&utm_campaign=share